115 related articles for article (PubMed ID: 26707218)
21. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
22. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
[TBL] [Abstract][Full Text] [Related]
23. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
[TBL] [Abstract][Full Text] [Related]
24. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Drazan D; Czajka H; Maguire JD; Pregaldien JL; Maansson R; O'Neill R; Anderson AS; Balmer P; Beeslaar J; Perez JL
Vaccine; 2022 Jan; 40(2):351-358. PubMed ID: 34961633
[TBL] [Abstract][Full Text] [Related]
25. Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.
Green LR; Eiden J; Hao L; Jones T; Perez J; McNeil LK; Jansen KU; Anderson AS
Methods Mol Biol; 2016; 1403():445-69. PubMed ID: 27076147
[TBL] [Abstract][Full Text] [Related]
26. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
[TBL] [Abstract][Full Text] [Related]
27. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
29. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
30. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
Carter NJ
BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
32. Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine.
Fiorito TM; Bornschein S; Mihalakos A; Kelleher CM; Alexander-Scott N; Kanadanian KV; Raymond P; Sicard K; Dennehy PH
J Am Coll Health; 2017; 65(4):294-296. PubMed ID: 28121236
[TBL] [Abstract][Full Text] [Related]
33. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
34. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
Shirley M; Taha MK
Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
[TBL] [Abstract][Full Text] [Related]
35. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
[TBL] [Abstract][Full Text] [Related]
38. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
39. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine.
Hong E; Terrade A; Taha MK
Hum Vaccin Immunother; 2017 Mar; 13(3):645-648. PubMed ID: 27808594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
